This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Vanda Pharmaceuticals, Inc.
Drug Names(s): iloperidone, Fiapta, ILO522, Zomaril, Fanapta, Fanaptum
Description: Fanapta is a second generation (atypical) antipsychotic agent, which acts as a dopamine D2/serotonin 5-HT2 receptor antagonist. Iloperidone has high affinity for the 5-HT2A, D2, and D3 receptors, a moderate affinity for D4, 5-HT6, 5-HT7, and alpha1 receptors, and low affinity for the 5-HT1A, D1, and H1 receptors.
As of Q4 2013, revenues are no longer reported for Fanapt. As such, BioMedTracker no longer forecasts revenues.
Revenue splits for this drug are BioMedTracker estimates.
Titan and sanofi-aventis
In January 1997, Titan Pharmaceuticals announced that it signed an agreement with Hoechst Marion Roussel (which became Aventis Pharmaceuticals, and subsequently Sanofi-Aventis) for an exclusive worldwide license to Fanapta.
Titan and Novartis
In November 1997, Titan granted a worldwide sublicense, except Japan, to Novartis under which Novartis will continue, at its expense, all further development of Fiapta. In April 2001, that sublicense was extended to include Japan. Novartis will make milestone payments to Aventis during the life of the Novartis agreement, and will also pay to Aventis and Titan a royalty on future net sales of the product. The royalty to Titan is 8% on the first $200 million of sales annually and 10% on all sales...See full deal structure in Biomedtracker
Partners: Titan Pharmaceuticals, Inc. Sanofi Biotoscana International MegaPharm Ltd.
Additional information available to subscribers only: